Condition: Sinonasal Undifferentiated Carcinoma · Sponsor: Istituti Clinici Scientifici Maugeri SpA
This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.
This description comes directly from the study's public registry record.
Serena Barbaro, M.Sc. · +39 (0)3982592326 · CTCstaff.pavia@icsmaugeri.it
Laura D Locati, MD, PhD · 0382592326 · lauradeborahlocati@icsmaugeri.it
Always discuss trial participation with your own doctor first.
| Istituti Clinici Scientifici Maugeri | Pavia, Lombardy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05925491